Skip to main content

Shashwatee Bagchi, MD

Academic Title:

Assistant Professor

Primary Appointment:



Institute of Human Virology, N157

Phone (Primary):

(410) 706-4606


(410) 706-3243

Education and Training


May 1993: University of Pennsylvania, Bachelor of Arts. Dual Majors: Biology and South Asian Regional Studies


June 1995:  Rosalind Franklin University of Medicine and Science, The Chicago Medical School, Masters of Science in Applied Physiology


June 1999:  Rosalind Franklin University of Medicine and Science, The Chicago Medical School, M.D


Post Graduate Education and Training

June 1999- June 2002: New York Presbyterian Hospital/Columbia Presbyterian Medical Center: Internal Medicine Residency


July 2002- June 2004:  Brigham and Women’s Hospital and Massachusetts General Hospital: Infectious Disease Fellowship


My academic background is rich in clinical, educational and international experiences. I worked as a research technician after my undergraduate years on various mutagenesis, subcloning and exon shuffling projects and utilized numerous immunology and molecular biology laboratory techniques. Since then, I have been engaged in clinical care and medical education. As the HIV Fellow in my Infectious Diseases fellowship program, I was engaged in the discussions about study design, recruitment, enrollment, and implementation of studies conducted through the Adult AIDS Clinical Trials Group at the Harvard site. After fellowship, I joined the faculty at University of Alabama at Birmingham to work in its large international program in sub-Saharan Africa at the epicenter of the global HIV/AIDS epidemic. While abroad, I submerged myself in delivering care to HIV-infected persons and training and mentoring physicians in HIV management. In my administrative role, I directed a large team of Tanzanian physicians and healthcare workers to implement HIV care and treatment programs throughout Tanzania. I actively participated in a number of research studies that led to three publications (listed below), including one relating fasting triglyceride levels to early mortality in persons on antiretroviral therapy and another describing cardiometabolic risk factors of patients initiating ART in Zambia.

Upon returning to the Unites States, I was immersed in clinical care and education and re-acquainted myself to standards of clinical practices here. I reflected on the evolution of the domestic HIV epidemic, and in the past two years became more interested in investigating cardiovascular disease (CVD) in HIV-infected patients given that it is the third leading cause of mortality in this population. In 2013, I began a retrospective study evaluating cardiovascular health in HIV-infected patients in an inner-city clinic in Baltimore, MD. Based on the preliminary findings of the study (manuscript under review), I began focusing on hepatitis C as a risk factor for CVD in HIV-infected patients. Since these research endeavors began,I have published two manuscripts, four are under review, and I am preparing two others currently. I believe my past experiences have trained me well to make timely and relevant clinical observations, carefully consider host immune pathways to explain mechanisms of diseases, and successfully conduct clinical trials that would test interventions in improving health outcomes. However, I need formal training, mentorship, and protected research time to learn specific lab skills and other research methodologies to develop into a successful independent investigator. 

Research/Clinical Keywords

Infectious Disease, Medicine, Prevention

Highlighted Publications

1. Bagchi S, Kempf MC, Westfall, AO, Maherya A, Willig J, and Saag MS.  Can Routine Clinical Markers be Used Longitudinally to Monitor Antiretroviral Therapy Success in Resource Limited Settings?  Clin Infect Dis.  January 2007; 44:135-138.


2.  Kiage JN, Heimburger DC, Nyirenda CK, Wellons MF, Bagchi S, Chi BH, Koethe JR, Arnett DK, and Kabagambe EK. Cardiometabolic risk factors among HIV patients on antiretroviral therapy.  Lipids in Health and Disease 2013; 12:50.


3.  Bagchi S, Patel P, Faramand R, Burrowes S, Hossain MB, Kottilil S, Miller M,  Fantry LE, and Redfield R.  Underutilization of Statins for Prevention of

Cardiovascular Disease Among Primarily African-American HIV-Infected Patients. J AIDS Clin Res 2015; 6:9.


4.  Adekunle R and Bagchi S. Review of Cardiovascular Disease in HIV-Infected Women. J AIDS Clin Res 2016; 7:3.


5. Hickey A and Bagchi S. Cardiovascular Disease Risk Assessment Tools in HIV-Infected Patients – Are They Adequate? J AIDS Clin Res 2016; 7:6.

Research Interests

HIV/ADIS, Infectious Disease

Grants and Contracts


09/01/06 - 08/31/07:        UAB CFAR (Heimburger, D.C., PI)                       

                                        Nutritional Causes of Early ART Mortality in Zambia

                                        Annual direct costs: $30,000

                                        Role: Co-investigator.                                       

Annual direct costs: $30,000

In a cohort of ART-naïve Zambians with HIV/AIDS who are starting ART at CIDRZ-supported sites and who exhibit major risk factors for early ART mortality (i.e., CD4+ count < 50 cells/mL or BMI < 16 kg/m2), we are (1) determining whether refeeding syndrome occurs, estimating its incidence and (2) examining whether persons who develop refeeding syndrome are at higher risk of early ART mortality or near-mortality than persons who do not develop refeeding syndrome.


03/01/03 - 02/14/08:        P30 AI27767 (Michael Saag, PI)                            

                                        UAB Center for AIDS Research                                                                Annual direct costs:  $1,112,341

                                        Role:  Co-investigator of International Core. 

The major objectives of the Center for AIDS Research are: (1) To enhance ongoing outstanding research programs by facilitating interdisciplinary interactions, providing critical shared resource facilities, and providing administrative and fiscal management support mechanisms for Center investigators; (2) To stimulate the entry of junior and established faculty into HIV/AIDS research programs. This will be accomplished through mentoring and training of your investigators and by the continuation of a peer-reviewed, competitive Developmental Grant Program that will provide funding for both developmental and pilot grants; and (3) To stimulate recruitment and program development efforts in AIDS-related areas. The Center has identified new program areas and will assist Departments and Divisions in the process of investigator recruitment. These approaches will ensure continued growth and development of AIDS-related research in the CFAR.


02/15/08- 12/31/10:         PEPFAR (Robert Redfield, PI) 

                                    University of Maryland School of Medicine, Institute of

                                    Human Virology

                                    Role: Infectious Disease faculty



7/1/2013- 6/30/2014:       New Investigator Award

                                        University of Maryland School of Medicine, Institute of

                                        Human Virology

                                        Direct costs: $20,000

                                        Role: Principal Investigator                                    

Cardiovascular Health of HIV-Infected Patients

The purpose of this study is to describe the cardiovascular health of HIV-infected individuals served by the Evelyn Jordan Center (EJC), an urban clinic where the patients are majority African Americans, almost half are women, and many are dependent on illegal substances. There were three main objectives: (1) To evaluate the annual rate of change in CVD risk, as assessed by the Framingham risk score (FRS), in HIV-infected patients enrolled in the EJC during June 1, 2008- May 31, 2012, (2) To identify sociodemographic and clinical factors that are associated with the change of the FRS in that time period, and (3) To determine if specific antiretroviral medications were associated with change of FRS in the EJC patient population. From this longitudinal retrospective cohort, we will be able to evaluate the changing cardiovascular risk factors during the four-year time period, establish a research database from the large clinical cohort, and generate hypotheses for future studies. The proposed study of this grant application arose from one of the analyses of these data, and we anticipate many more since the data collection is ongoing.


8/1/2015-8/31/2019: 5RO1HL125060-02 (Sanjay Rajagopalan, PI)         


                                 Role: Sub-investigator 

EXercise MRI evaluation of HIV-PAH Longitudinal Determinants (EXHALTED)

The purpose of this grant is to investigate a novel use of MRI technology with a detailed assessment of cardiopulmonary indices to provide information on the prevalence and progression of PAH and progressive impairment in contractile function of the RV that commonly afflicts HIV patients. We will further analyze inflammatory variables that may predict these changes thus allowing early identification of these patients.




01/01/11- present: Title IX Ryan White Grant Award (Robert Redfield, PI)

                              Maryland Department of Health and Mental Hygeine

                              Role: Sub-investigator


The purpose of the service grant award is to provide comprehensive, quality health care services to HIV-infected patients living in the State of Maryland.


06/01/17- 05/31/22: K23 HL133358-01A1 (Shashwatee Bagchi, PI)


                                 Role: PI

Elucidating Chronic Hepatitis C Infection as a Risk Factor for Coronary Heart Disease in HIV-Infected Patients

The purpose of this grant is to support the scientific career development of the Principal Investigator to achieve independence as a clinical investigator in an academic institution and to contribute to the field of discovery in HIV/AIDS and hepatitis C. The goal of this research project is to establish the extent to which chronic hepatitis C infection increases the burden of coronary heart disease (CHD) in HIV-infected patients, and to elucidate host inflammatory and immune pathways that predict increased CHD burden.